Verteporfin: A review of its use in the management of subfoveal choroidal neovascularisation

Drugs and Aging

Volumn 23, Issue 5, 2006, Pages 421-445

  Fenton, Caroline ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Age related macular degeneration; Choroidal neovascularisation; Pathological myopia; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Tolerability; Verteporfin

Indexed keywords

ANECORTAVE; BENZOPORPHYRIN DERIVATIVE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE;

ASTHENIA; BACKACHE; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; CYTOTOXICITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL HEMORRHAGE; HALF LIFE TIME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERSENSITIVITY; INJECTION SITE REACTION; META ANALYSIS; MYOPIA; NAUSEA; PHOTOSENSITIVITY; PRIORITY JOURNAL; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SLEEP DISORDER; SUBRETINAL NEOVASCULARIZATION; SYSTEMATIC REVIEW; VISUAL ACUITY; VISUAL DISORDER;

AGING; CHOROIDAL NEOVASCULARIZATION; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DATABASES, BIBLIOGRAPHIC; DRUG UTILIZATION; EYE; FOVEA CENTRALIS; HUMANS; MACULAR DEGENERATION; MYOPIA, DEGENERATIVE; PORPHYRINS; TREATMENT OUTCOME;

EID: 33745964142     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623050-00006     Document Type: Review

References (99)

1. Comer GM, Ciulla TA, Criswell MH, et al. Current and future treatment options for nonexudative and exudative age-related macular degeneration. Drugs Aging 2004; 21 (15): 967-92
2. European Medicines Agency. Visudyne [online]. Available from URL: http://www.emea.eu.int [Accessed 2005 Sep 19]
3. International Council of Ophthalmology. Visual standards - aspects and ranges of vision loss [online]. Available from URL: http://www.icoph.org [Accessed 2005 Sep 28]
4. Smith W, Assink J, Klein R, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001 Apr; 108 (4): 697-704
5. Thornton J, Edwards R, Mitchell P, et al. Smoking and age-related macular degeneration: a review of association. Eye 2005 Sep; 19 (9): 935-44
6. Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS Report No. 19. Ophthalmology 2005; 112 (4): 533-9
7. Schmidt S, Haines JL, Postel EA, et al. Joint effects of smoking history and APOE genotypes in age-related macular degeneration. Mol Vis 2005 Nov; 11: 941-9
8. Arnold J, Sarks S. Age related macular degeneration. Clin Evid 2004 Jun; (11): 819-34
9. Wong TY, Foster PJ, Hee J, et al. Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Invest Ophthal Vis Sci 2000 Aug; 41 (9): 2486-94
10. Early Treatment Diabetic Retinopathy Study Group. Early Treatment Diabetic Retinopathy Study design and patient characteristics. ETDRS Report Number 7. Ophthalmology 1991; 98: 741-56
11. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991; 109: 1242-57
12. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes - TAP Report No. 3. Arch Ophthalmol 2002 Nov; 120 (11): 1443-54
13. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001 Feb; 119 (2): 198-207
14. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol 1999; 117: 1329-45
15. Rubin GS, Bressler NM, and the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast sensitivity: results from the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Investigation - TAP Report No. 4. Retina 2002 Oct; 22 (5): 536-44
16. VAM Study Writing Committee. Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients. VAM Study Writing Committee. Retina 2004 Aug; 24 (4): 512-20
17. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005 Apr; 123 (4): 448-57
18. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001 May; 131: 541-60
19. Novartis Pharmaceutical Corporation. Prescribing information: Visudyne® (verteporfin for injection) [online]. Available from URL: http://www.visudyne.com [Accessed 2005 Nov 17]
20. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000; 45 (3): 195-214
21. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005; 25 (2): 119-34
22. Eter N, Spaide RF. Comparison of fluorescein angiography and optical coherence tomography for patients with choroidal neovascularization after photodynamic therapy. Retina 2005 Sep; 25 (6): 691-6
23. National Eye Institute. Vision problems in the US [online]. Available from URL: http://www.nei.nih.gov [Accessed 2005 Sep 5]
24. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP Report No. 2. Arch Ophthalmol 2003 Sep; 121 (9): 1253-68
25. la Cour M. Photodynamic therapy for AMD: smaller is better! Acta Ophthalmol Scand 2004 Dec; 82 (6): 641-2
26. Jonas JB. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration [letter]. Am J Ophthalmol 2002 Jun; 133 (6): 857; author reply 857-9
27. Frederick DR. Myopia. BMJ 2002 May 18; 324: 1195-9
28. Keam SJ, Scott LJ, Curran MP. Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation. Drugs 2003; 63 (22): 2521-54
29. Ratkay LG, Waterfield JD, Hunt DWC. Photodynamic therapy in immune (non-oncological) disorders: focus on benzoporphyrin derivatives. Biodrugs 2000 Aug; 14: 127-35
30. Allison BA, Pritchard PH, Levy JG. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative [published erratum appears in Br J Cancer 1995 Jan; 71(1): 214]. Br J Cancer 1994; 69: 833-9
31. Weinberger D, Ron Y, Lusky M, et al. Competitive quenching: a possible novel approach in protecting RPE cells from damage during PDT. Curr Eye Res 2005 Apr; 30 (4): 269-77
32. Huang Y, Obana A, Gohto Y, et al. Comparative study of the phototoxicity of two chrolin type photosensitizers, ATX-S10(Na) and verteporfin, on vascular endothelial and retinal pigment epithelial cells. Lasers Surg Med 2004; 34 (3): 216-26
33. Schmidt-Erfurth U, Hasan T, Gragoudas E, et al. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994; 101: 1953-61
34. Paskowitz DM, Nune G, Yasumura D, et al. BDNF reduces the retinal toxicity of verteporfin photodynamic therapy. Invest Ophthalmol Vis Sci 2004 Nov; 45 (11): 4190-6
35. Renno RZ, Terada Y, Haddadin MJ, et al. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol 2004 Jul; 122 (7): 1002-11
36. Grisanti S, Tatar O, Canbek S, et al. Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy. Am J Ophthalmol 2004 May; 137 (5): 914-23
37. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003 Oct; 44 (10): 4473-80
38. Lanzetta P, Parodi MB, Ambesi-Impiombato M, et al. Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2004 Oct; 242 (10): 840-4
39. Houle J-M, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol 2002 May; 42 (5): 547-57
40. Desmettre T, Mordon SR. Comparison of laser beam intensity profiles produced by photodynamic therapy (PDT) and transpupillary thermotherapy (TTT) lasers. Lasers Surg Med 2005; 36 (4): 315-22
41. Sharma RK, Orr WE, Schmitt AD, et al. A functional profile of gene expression in ARPE-19 cells. BMC Ophthalmol 2005 Nov 1; 5: 25
42. Michels S, Hansmann F, Geitzenauer W, et al. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006 Jan; 47 (1): 371-6
43. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial - VIP Report No. 1. Ophthalmology 2001 May; 108 (5): 841-52
44. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial - VIP Report No. 3. Ophthalmology 2003; 110: 667-73
45. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age- related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP Report No. 5. Arch Ophthalmol 2002 Oct; 120 (10): 1307-14
46. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7 [letter]. Arch Ophthalmol 2005 Sep; 123 (9): 1283-5
47. Japanese Age-Related Macular Degeneration Trial (JAT) Study Group. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003 Dec; 13 (6): 1049-61
48. Barnes RM, Gee L, Taylor S, et al. Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation-'beyond the TAP study'. Eye 2004 Aug; 18 (8): 809-13
49. Yang N, Fan CM, Ho CK. Review of first year result of photodynamic therapy on age-related macular degeneration in chinese population. Eye 2005 Aug 5
50. VIP Report No. 5 Writing Committee. Verteporfin in Photodynamic Therapy: Report No. 5 [letter]. Ophthalmology 2004 Nov; 111 (11): 2144
51. Lam DS, Chan W-M, Liu DT, et al. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularisation of pathologic myopia in Chinese eyes: a prospective series of 1 and 2 year follow up. Br J Ophthalmol 2004 Oct; 88 (10): 1315-9
52. Bandello F, Lanzetta P, Parodi MB, et al. Photodynamic therapy of subfoveal recurrences after laser photocoagulation of extrafoveal choroidal neovascularization in pathologic myopia. Graefes Arch Clin & Exp Ophthalmol 2003 Jul; 241 (7): 567-70
53. Krebs I, Binder S, Stolba U, et al. Choroidal neovascularisation in pathologic myopia: three-year results after photodynamic therapy. Am J Ophthalmol 2005 Sep; 140 (3): 416-25
54. Axer-Siegel R, Ehrlich R, Weinberger D, et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: visual outcome in relation to age at treatment. Am J Ophthalmol 2004 Oct; 138 (4): 602-7
55. Ergun E, Heinzl H, Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 2004 Sep; 138 (3): 434-8
56. Schmidt-Erfurth UM, Elsner H, Terai N, et al. Effects of verteporfin therapy on central visual field function. Ophthalmology 2004 May; 111 (5): 931-9
57. Writing Committee for the TAP Study Group. Improvement after verteporfin therapy [letter]. Arch Ophthalmol 2003 Mar; 121 (3): 415-6
58. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP Report No. 1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Group and Verteporfin in Photodynamic Therapy study groups. Am J Ophthalmol 2003 Sep; 136 (3): 407-18
59. Harding S. Photodynamic therapy in the treatment of subfoveal choroidal neovascularisation. Eye 2001 Jun; 15 (Pt 3): 407-12
60. Brown GC, Brown MM, Campanella J, et al. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration-a value-based reappraisal with 5-year data. Am J Ophthalmol 2005 Oct; 140 (4): 679-87
61. Kaiser PK. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension TAP Report No. 8. Graefes Arch Clin Exp Ophthalmol. Epub 2006 Mar 15
62. Writing Committee for the VIP Study Group. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration. Arch Ophthalmol 2006; 124: 660-4
63. US National Institutes of Health. Visudyne® in occult (VIO) [online]. Available from URL: http://www.clinicial trials.gov [Accessed 2005 Oct 5]
64. QLT Inc. QLT announces two year results of Visudyne® in occult (VIO) trial [media release] [online]. Available from URL: http://www.qltinc.com [Accessed 2005 Oct 20]
65. Two-year results of the VIM trial. Rochester (MI): Novartis Pharma AG, 2006. (Data on file)
66. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials - TAP and VIP Report No. 3. Am J Ophthalmol 2004 Apr; 137 (4): 683-96
67. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy (VIP) Study Groups. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report No. 4. Retina 2004 Feb; 24 (1): 1-12
68. Gelisken F, Inhoffen W, Karim-Zoda K, et al. Subfoveal hemorrhage after verteporfin photodynamic therapy in treatment of choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2005 Mar; 243 (3): 198-203
69. Bhatnagar A, Musadiq M, Yang YC. Late-onset visual decline following successful treatment of subfoveal choroidal neovascularisation with photodynamic therapy. Eye 2006; 20: 491-3
70. Sharma S, Brown GC, Brown MM, et al. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2001; 108: 2051-9
71. Smith DH, Fenn P, Drummond M. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case. Br J Ophthalmol 2004 Sep; 88 (9): 1107-12
72. Greiner RA. Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Semin Ophthalmol 2001; 16 (4): 218-22
73. Wormald R, Evans J, Smeeth L, et al. Photodynamic therapy for neovascular age-related macular degeneration (Review). Cochrane Database Syst Rev 2005 Oct 19; 4: CD002030
74. Brown GC, Brown MM, Sharma S, et al. Incremental cost-effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology 2000; 107 (1374-80)
75. Busbee BG, Brown M, Brown GC, et al. CME Review: a cost utility analysis of lase photocoagulation for extrafoveal choroidal neovascularization. Retina 2003; 23: 279-87
76. Sharma S, Hollands H, Brown GC, et al. Improvement in quality of life from photodynamic therapy: a Canadian perspective. Can J Ophthalmol 2001; 36: 332-8
77. QLT Inc. QLT announces reimbursement for Visudyne® in Japan for treatment of age-related macular degeneration [media release] [online]. Available from URL: http://www.qltinc.com [Accessed 2005 Oct 20]
78. Liu M, Regillo CD. A review of treatments for macular degeneration: a synopsis of currently approved treatments and ongoing clinical trials. Curr Opin Ophthalmol 2004 Jun; 15 (3): 221-6
79. Pauleikhoff D, Bornfeld N, Gabel VP, et al. The position of the retinological society, the German ophthalmological society and the professional association of ophthalmologists - comments on the current therapy for neovascular AMD [abstract only] [in German]. Klin Monatsbl Augenheilkd 2005 May; 222 (5): 381-8
80. Pfizer Inc. Macugen® (pegaptanib sodium injection) prescribing information [online]. Available from URL: http://www.macugen.com/macugen_PI.pdf [Accessed 2005 Oct 12]
81. Genentech Inc. Preliminary data from phase III trial show Lucentis is the first investigational therapy to demonstrate clinical benefit over Visudyne in a head-to-head study of patients with wet AMD [media release] [online]. Available from URL: http://www.gene.com [Accessed 2005 Nov 7]
82. Kaiser PK. Verteporfin therapy in combination with triamcinolone: published studies investigating a potential synergistic effect. Curr Med Res Opin 2005 May; 21 (5): 705-13
83. Slakter JS, Bochow TW, D'Amico DJ, et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006 Jan; 113 (1): 3-13
84. Conti SM, Kertes PJ. Surgical management of age-related macular degeneration. Can J Ophthalmol 2005 Jun; 40 (3): 341-51
85. International Council of Ophthalmology. Age-related macular degeneration (management recommendations) [online]. Available from URL: http://www.icoph.org [Accessed 2005 Oct 12]
86. The Royal College of Ophthalmologists. Guidance February 2001: Photodynamic therapy in the management of subfoveal choroidal neovascularisation secondary to age-related macular degeneration [online]. Available from URL: http://www.rcophth.ac.uk [Accessed 2005 Oct 12]
87. American Academy of Ophthalmology. Age-related macular degeneration [online]. Available from URL: http://www.guideline.gov [Accessed 2005 Oct 12]
88. National Institute for Clinical Excellence. Technology Appraisal Guidance 68. Photodynamic therapy for age-related macular degeneration [online]. Available from URL: http://www.nice.org.uk [Accessed 2005 Oct 12]
89. Kaiser RS, Berger JW, Williams GA, et al. Variability in fluorescein angiography interpretation for photodynamic therapy in age-related macular degeneration. Retina 2002 Dec; 22 (6): 683-90
90. Schein OD, Bressler NM, Price P. Photodynamic therapy with verteporfin: observations on the introduction of a new treatment into clinical practice. Arch Ophthalmol 2005 Jan; 123 (1): 58-63
91. Bressler SB, Pieramici DJ, Koester JM, et al. for the TAP Study Group. Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management - TAP Report No. 6. Arch Ophthalmol 2004 Mar; 122 (3): 325-9
92. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. American Academy of Ophthalmology 2006; 113: 14-22
93. US National Institutes of Health. Verteporfin clinical trials [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2005 Dec 13]
94. Wachtlin J, Stroux A, Wehner A, et al. Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV. Graefes Arch Clin Exp Ophthalmol 2005 May; 243 (5): 438-45
95. Michels S, Wachtlin J, Gamulescu MA, et al. Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration. Ophthalmology 2005 Dec; 112 (12): 2070-5
96. Chakravarthy U, Stevenson M. Self-reported visual functioning and quality of life in age-related macular degeneration. Curr Opin Ophathalmol 2005; 16: 179-83
97. Armbrecht AM, Aspinall PA, Dhillon B. A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. Br J Ophthalmol 2004 Oct; 88 (10): 1270-3
98. Krummenauer F, Braun M, Dick HB. Clinical outcome and subjective quality of life after photodynamic therapy in patients with age-related macular degeneration. Eur J Ophthalmol 2005; 15 (1): 74-80
99. Sternberg Jr P, Lewis H. Photodynamic therapy for age-related macular degeneration: a candid appraisal. Am J Ophthalmol 2004 Mar; 137 (3): 483-5